2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide | 1228024-50-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide
• 英文别名: 2,2-Dicyclohexyl-N-((3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)acetamide；N-[(3aS,4S,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide
• CAS: 1228024-50-7
• 化学式: C₂₁H₃₆N₂O
• 分子量: 332.53
• InChiKey: LCHOSRIKTHYCQA-OTWHNJEPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide 、 对氟苯甲醛 在 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide
  参考文献：
  名称：

  Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca2+ channel blockers with analgesic activity

  摘要：

  A novel 4-aminocyclopentapyrrolidine series of N-type Ca2+ channel blockers have been discovered. Enantioselective synthesis of the 4-aminocyclopentapyrrolidines was enabled using N-tert-butyl sulfinamide chemistry. SAR studies demonstrate selectivity over L-type Ca2+ channels. N-type Ca2+ channel blockade was confirmed using electrophysiological recording techniques. Compound 25 is an N-type Ca2+ channel blocker that produces antinociception in inflammatory and nociceptive pain models without exhibiting cardiovascular or motor liabilities. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.057
• 作为产物：
  描述：

  (1R*,5S*)-N-benzyl-3-azabicyclo<3.3.0>octan-8-one 在 盐酸 、 titanium(IV) tetraethanolate 、 sodium tetrahydroborate 、 20 % Pd(OH)2/C 、 水 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， -78.0~60.0 ℃ 、206.85 kPa 条件下， 反应 68.5h， 生成 2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide
  参考文献：
  名称：

  Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca2+ channel blockers with analgesic activity

  摘要：

  A novel 4-aminocyclopentapyrrolidine series of N-type Ca2+ channel blockers have been discovered. Enantioselective synthesis of the 4-aminocyclopentapyrrolidines was enabled using N-tert-butyl sulfinamide chemistry. SAR studies demonstrate selectivity over L-type Ca2+ channels. N-type Ca2+ channel blockade was confirmed using electrophysiological recording techniques. Compound 25 is an N-type Ca2+ channel blocker that produces antinociception in inflammatory and nociceptive pain models without exhibiting cardiovascular or motor liabilities. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.04.057

文献信息

• NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS
  申请人：Stewart Andrew O.

  公开号：US20100130558A1

  公开（公告）日：2010-05-27

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L 1 , L 2 , R 1 , R 2 , and R 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式（I）化合物的钙通道抑制剂，其中L1、L2、R1、R2和R3如规范中所定义。本申请还涉及包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] BENZODIAZEPINE COMPOUNDS USEFUL FOR THE TREATMENT OF HEPATITIS C<br/>[FR] COMPOSÉS DE BENZODIAZÉPINE UTILES POUR LE TRAITEMENT DE L'HÉPATITE C
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2011151651A1

  公开（公告）日：2011-12-08

  The invention concerns benzodiazepine derivatives of Formula (I) wherein A, X, L1, L2, R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the treatment or prophylaxis of hepatitis C virus infection.

  这项发明涉及式（I）的苯二氮卓啉衍生物，其中A、X、L1、L2、R1、R2、R3、R4、R5、R6和R7如描述中所定义。本发明还涉及制备这类化合物的方法、含有它们的药物组合物以及它们在治疗或预防丙型肝炎病毒感染中的用途。
• Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers
  申请人：Abbott Laboratories

  公开号：US08129417B2

  公开（公告）日：2012-03-06

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本申请涉及含有式(I)中定义的L1、L2、R1、R2和R3的钙通道抑制剂化合物。本申请还涉及包含这些化合物的组合物以及使用这些化合物和组合物治疗疾病和疾病的方法。
• US8129417B2
  申请人：——

  公开号：US8129417B2

  公开（公告）日：2012-03-06
• [EN] NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS<br/>[FR] NOUVELLES OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES SUBSTITUÉES COMME BLOQUEURS DE CANAUX CALCIQUES
  申请人：ABBOTT LAB

  公开号：WO2011149995A1

  公开（公告）日：2011-12-01

  The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.